Bing

SEARCH HISTORY

Sanofi‘s (NYSE:SNY) Fabrazyme costs around $200,000/year ... healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last …
INSIDER MONKEY · 7/24/2015
Amicus
Many investors like to look for value in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately ...
ZACKS · 7/9/2015
Cost-cutting, downsizing, emerging markets and new products should support growth. Among pharma stocks, companies like Bayer (BAYRY), Lilly (LLY) and Sanofi (SNY) are all Zacks Rank #2 (Buy) stocks. In the biotech space, we are positive on …
Yahoo News · 7/22/2015
pharma
Baseball analyst Ron Darling, who covers the Mets for SNY, came up with his all-underrated MLB team. Here are his selections: 1B — Edwin Encarnacion (Blue Jays); 2B — Jason Kipnis (Indians); SS — Alcides Escobar (Royals); 3B — Kyle Seager …
Watertown Daily Times · 7/28/2015
Disposition of 192,501 shares of Common Stock to satisfy withholding taxes on vesting of 500,000 ... Issues Q3 Outlook Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of Praluent FCC Grants Approval of AT&T (T), DIRECTV (DTV) Deal
StreetInsider · 7/24/2015
U.S. stocks advanced once again on Wednesday ... AstraZeneca (AZN) reported better than expected second quarter earnings on strong drug sales. Sanofi's (SNY) second quarter earnings also rose year-over-year. Alcatel-Lucent (ALU), which is set to be ...
Realtime Business News · 7/30/2015
Quarter Growth Soft
This continues the recent downtrend for SNY, as the stock is now down about 14% in the past one-month time frame. This slump shouldn't be too much of a surprise to investors, as this drug manufacturer company has seen two negative revisions in the …
NASDAQ · 10/29/2014
Scynexis went public last year, raising $54.6 million. In May, the company completed a $37.7 million follow-on stock offering, which it said would finance mid-stage clinical trials of the pill version of its antifungal, as well …
Xconomy · 7/23/2015
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). About Regeneron Pharmaceuticals, Inc. Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents …
Stock World · 7/28/2015
Sanofi (SNY)’s monthly performance stand at – 1.31% with a profit margin of 12.60% and has an analyst rating of 1.7 (Click To Expand Current Stock Data:) DryShips, Inc. (DRYS) of the Services sector (Shipping) is up 6.14% already this morning ...
wallstreetscope.com · 7/10/2015